Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (Nasdaq: CLSD) announced that its Chief Medical Officer, Thomas A. Ciulla, will present at the Needham Virtual Healthcare Conference on April 13, 2022, at 3:45 p.m. ET. The presentation will highlight Clearside's innovative approach to delivering therapies to the back of the eye through the suprachoroidal space (SCS).

For those interested, a live and archived webcast will be accessible on the Clearside website under the Investors section.

Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.

Clearside Biomedical (NASDAQ:CLSD) reported a significant milestone of $20 million in non-dilutive funding in Q4 2021, primarily from XIPERE commercialization partners. The company's license revenue for Q4 2021 soared to $25.7 million compared to just $11,000 in Q4 2020. A net income of $18.7 million was achieved, reflecting a marked improvement over the prior year's loss. The ongoing Phase 1/2a OASIS trial of CLS-AX for wet AMD is progressing, with results from Cohort 3 anticipated mid-2022 and a new Cohort 4 planned. Management will provide updates through a conference call today.

Clearside Biomedical has appointed Dr. Benjamin R. Yerxa to its Board of Directors, effective March 2, 2022. Dr. Yerxa, CEO of the Foundation Fighting Blindness, brings over 25 years of experience in ophthalmology and biotechnology. His insight will support the advancement of CLS-AX, a treatment targeting wet age-related macular degeneration. The company continues to develop its proprietary SCS injection platform, which enables targeted therapy delivery to the eye. Clearside aims to play a vital role in treating sight-threatening diseases amidst a growing need in the healthcare sector.

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, a biopharmaceutical company, announced its participation in two investor conferences in March 2022. The company will present at the 42nd Annual Cowen Health Care Conference on March 8 at 9:50 am ET and the 34th Annual ROTH Conference from March 14-15 in Dana Point, CA. Investors can access live and archived webcasts on the Clearside website. The company focuses on innovative therapies delivered to the back of the eye via its proprietary SCS Microinjector.

Clearside Biomedical (NASDAQ:CLSD) will report its fourth quarter and full year 2021 financial results on March 10, 2022, post-market. A conference call and webcast will follow at 4:30 PM ET for discussion and corporate updates. Clearside is known for its innovative suprachoroidal space (SCS) technology that enhances therapy delivery to the eye. Their first product, XIPERE™, was FDA-approved in October 2021, marking a significant advancement in vision-preserving treatments.

Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations on its suprachoroidal injection platform at the Bascom Palmer Eye Institute event held on February 11-12, 2022. The presentations highlighted the advantages of using the SCS Microinjector for targeted delivery of therapies to the retina. Preclinical studies suggest superior performance compared to traditional methods. Additionally, REGENXBIO shared positive interim data from its Phase 2 trial of RGX-314 for diabetic retinopathy, showing significant patient improvement with no serious adverse effects.

Clearside Biomedical (Nasdaq: CLSD) announced its suprachoroidal space (SCS) injection platform will be featured at key medical events in February 2022. This includes oral presentations at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration Virtual Event, where updates on gene therapy RGX-314 will also be shared. Additionally, Clearside will participate in the Raymond James Preview event discussing novel injectable approaches for anti-VEGF therapy. The SCS Microinjector is highlighted for its potential to improve targeted delivery of treatments for retinal diseases.

Clearside Biomedical has reported positive safety results from its ongoing Phase 1/2a clinical trial of CLS-AX for treating wet age-related macular degeneration (AMD). The 0.1 mg dose in Cohort 2 (n=5) was well tolerated with no serious adverse events. The Safety Monitoring Committee approved advancing to Cohort 3, which will use a 0.5 mg dose. Patients in Cohorts 1 and 2 showed stable visual acuity and minimal retreatment visits, indicating potential efficacy. The company anticipates further data gathering, with patient screening for the next cohort already underway.